All News
Cytokine Inhibitor Lung Disease in Still's Linked to HLA-DRB1 Alleles
Pulmonary complications in the setting of Still's disease (juvenile and adult) has seldom but consistently been reported, including reports of pneumonitis, pulmonary hypertension and a severe or fatal lung disease, often associated with hypersensitivity to anticytokine therapy. A multicenter study reports that drug hypersensitivity and pulmonary reactions in Still's patients receiving IL-1 or IL-6 inhibitors is strongly associated with HLA-DRB1*15 haplotypes.
Read Article
Prolonging the Controversy of Hydroxychloroquine
Since the start of the pandemic, hydroxychloroquine (HCQ) was forced into the limelight for the prevention/treatment of COVID-19. When it was found to be ineffective for COVID-19 and might cause potential harm, the drug came under closer scrutiny for its safety profile.
Read Article
DORIS - Defining Remission in Lupus
Proponents of treat to target in systemic lupus erythematosus (SLE) have all agreed that "remission" should be the goal, but defining remission may be tricky in SLE. A SLE Definitions Of Remission (DORIS)Task Force was convened in 2015 and first published their work in 2016.
Read Article
RheumNow Podcast - 60/40/20 Interview with Dr. Ed Keystone
Dr. Jack Cush interviews Professor Edward Keystone, MD (University of Toronto) on the origins and science behind the 60/40/20 benchmark and outcomes in rheumatoid arthritis.
Read Article
Safety of Psoriatic Biologics in Pregnancy
Little is known about the safety of newer biologic use during pregnancy, especially in patients who either conceive while on a biologic or must remain on a biologic during pregnancy (often the case with IBD and inflammatory arthritis).
Read Article
Does Control of Inflammation Lower Cancer Risk?
Dr. Jonathan Kay's provocative video addresses whether the increased cancer risk associated with tofacitinib (Tofa) seen in the Pfizer Oral Surveillance (1133) study represents a real increased risk, an increased risk relative to a decreased risk with TNF inhibitors (TNFi) or an actual decreased cancer risk (unknown as there was no placebo comparator in this trial).
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Improving Rheumatology Practice
How to best book patient appointments in rheumatology clinic? Should these be scheduled every 3 or 4 months regardless of patient status? Should they be scheduled by patient need or disease activity?
Read Article
Links:
RheumNow Podcast - Unwillingness to Change Therapy (11.19.21)
Surely you’ve seen this or been plagued by this patient, one that is not doing well, in need of a new regimen; you outline it, timeline it, define the side effects and send them off with a new prescription..
Read Article
GLORIA Study - Is Prednisone Harmful in Elder RA?
The GLORIA study (ABST# 1678) was a pragmatic, blinded placebo-controlled randomized trial from Dr. Martin Boers and colleagues where they assessed whether prednisolone (vs. placebo) use would alter clinical outcomes over 2 years.
Read Article
An Old Friend – Methotrexate in Psoriatic Arthritis
Methotrexate (MTX) remains one of our most used and reliable tools against a variety of rheumatic diseases, including PsA. When the time comes, as it often does, to escalate from a MTX-monotherapy approach, we have several options. In clinic, initiation of these other medications has often been in the form of addition rather than substitution. But what do the patients want, and how much more is the MTX adding in those cases?
Read Article
RheumNow Podcast - ACR 2021 Rehash (the good stuff..)
The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.
Read Article
ACR21 Best Abstracts - Day 4
On the last day of ACR21 Annual Meeting, the RheumNow faculty selected these 15 as their favorite reports.
Read Article
ACR21 – Day 3 Report
Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: secukinumab efficacy in juvenile PsA; VEXAS - predicting poor outcomes; and the FDA Safety Update session.
Read Article
Eric Dein ericdeinmd ( View Tweet)
Links:
